NovoCure Ltd. (NASDAQ:NVCR) saw unusually-strong trading volume on Thursday . Approximately 459,197 shares changed hands during trading, an increase of 84% from the previous session’s volume of 249,292 shares.The stock last traded at $7.75 and had previously closed at $7.68.

Several equities research analysts have recently commented on NVCR shares. Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of NovoCure in a research report on Tuesday, May 10th. Zacks Investment Research lowered shares of NovoCure from a “hold” rating to a “sell” rating in a research report on Friday, May 13th. Barclays PLC reduced their price target on shares of NovoCure from $12.00 to $9.00 and set an “underweight” rating for the company in a research report on Friday, July 29th. Deutsche Bank AG reduced their price target on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating for the company in a research report on Friday, July 29th. Finally, JMP Securities reduced their price target on shares of NovoCure from $43.00 to $34.00 and set a “market outperform” rating for the company in a research report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $21.43.

The firm’s market capitalization is $690.48 million. The firm has a 50-day moving average of $8.80 and a 200-day moving average of $11.68.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.11. The business earned $17.90 million during the quarter, compared to analyst estimates of $15.90 million. Analysts anticipate that NovoCure Ltd. will post ($1.74) earnings per share for the current fiscal year.

In other NovoCure news, COO Michael J. Ambrogi sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $12.24, for a total value of $244,800.00. Following the completion of the sale, the chief operating officer now owns 324,084 shares of the company’s stock, valued at $3,966,788.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Gert L. Perlhagen sold 676,576 shares of the firm’s stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $1.85, for a total value of $1,251,665.60. Following the completion of the sale, the director now directly owns 676,576 shares of the company’s stock, valued at approximately $1,251,665.60. The disclosure for this sale can be found here.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.